ALTERITY THERAPEUTICS LTD
About ALTERITY THERAPEUTICS LTD
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $70.7M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $70.7M
- Shares outstanding
- 18.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 4, 1992
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ALTERITY THERAPEUTICS LTD.
Write a review
News about ALTERITY THERAPEUTICS LTD
News & sentiment via Polygon.io
